Rxo (RXO) Receivables - Other (2021 - 2025)

Rxo (RXO) has reported Receivables - Other for 5 consecutive years, with $26.0 million the latest figure, recorded in Q4 2025.

• Receivables - Other for Q4 2025 came in at $26.0 million, up 52.94% year-over-year; the trailing twelve-month figure through Dec 2025 was $26.0 million (up 52.94% YoY), and the FY2025 annual result was $26.0 million, up 52.94% from the prior year.
• Receivables - Other was $26.0 million for Q4 2025 at Rxo, up from $17.0 million in the prior quarter.
• Over five years, Receivables - Other peaked at $26.0 million in Q4 2025 and troughed at $5.0 million in Q3 2022.
• Average Receivables - Other over 5 years is $13.8 million, with a median of $11.0 million recorded in 2023.
• Year-over-year, Receivables - Other jumped 54.55% in 2024 and jumped 52.94% in 2025.
• Over 5 years, Receivables - Other stood at $10.0 million in 2021, then sank by 50.0% to $5.0 million in 2022, then jumped by 120.0% to $11.0 million in 2023, then surged by 54.55% to $17.0 million in 2024, then soared by 52.94% to $26.0 million in 2025.
• Per Business Quant data, the three most recent Receivables - Other figures were $26.0 million in Q4 2025, $17.0 million in Q4 2024, and $11.0 million in Q4 2023.